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Pluripotent stem cells hold enomous potential for therapuetic applications in tissue replacement
therapy. Reprogramming somatic cells from a patient donor to generate pluripotent stem cells
involves both ethical concerns inherent in the use of embryonic and oocyte-derived stem cells, as
well as issues of histocompatibility. Among the various pluripotent stem cells, induced pluripotent
stem cells (iPSC)—derived by ectopic expression of four reprogramming factors in donor somatic
cells—are superior in terms of ethical use, histocompatibility, and derivation method. However, iPSC
also show genetic and epigenetic differences that limit their differentiation potential, functionality,
safety, and potential clinical utility. Here, we discuss the unique characteristics of iPSC and
approaches that are being taken to overcome these limitations.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction procedure does not require destruction of viable embryos, as pESCEmbryonic stem cells (ESC) are present in the inner cell mass
(ICM) of a blastocyst-stage embryo. Compared with other somatic
cells, ESC have two unique properties—self-renewal and pluripo-
tency. With these two properties, ESC represent an unlimited
source of tissue (self-renewal), and can generate any type of tissue
(pluripotency). However, the use of ESC for tissue replacement or
transplantation not only raises signiﬁcant ethical concerns, but
also requires the creation of a large stem cell bank in order to pro-
duce tissues that could be immunologically matched with any re-
cipient patient. Generation of ESC by somatic cell nuclear transfer
to an enucleated oocyte (ntESC) has been proposed as an alterna-
tive source of transplantable cells and tissues, primarily because
this technique may provide genetically identical and immunologi-
cally compatible stem cells for individual somatic cell donors (i.e.,
patient recipients; Fig. 1) [1]. Unfortunately, this method is both
cumbersome and inefﬁcient.
Yet another technique has been proposed for producing histo-
compatible stem cells suitable for tissue replacement therapy:
the generation of parthenogenetic ESC (pESC) (Fig. 1). Thisal Societies. Published by Elsevierare derived from unfertilized oocytes that have the potential to de-
velop into only a limited number of tissues [2,3]. In addition, pESC
appear to have fewer epigenetic abnormalities than ntESC because
the nuclear transfer technique requires reversion of the epigenetic
status of a terminally differentiated adult somatic cell nucleus to
an embryonic stage, whereas pESC are already at an embryonic
stage. However, pESC have a haploid duplicated homozygous gen-
ome [4,5] and large duplicated regions of homozygosity, which,
theoretically, might trigger natural killer cell-mediated immune
rejection if these cells are used for tissue replacement therapy
[6]. Clinically, partial major histocompatibility complex (MHC)
antigen matching enhances allograft survival, but fully MHC-
matched tissues are the most favorable for transplant [7]. There-
fore, an alternative method for generating pESC that are fully
matched to the oocyte donor/patient recipient has been developed,
in which a subset of pESC that have undergone crossing-over
events in their leukocyte antigen region during meiosis are se-
lected [8,9]. Nonetheless, pESC are generated from donor eggs,
which means that this approach can only be applied to female
patients.
Generation of ESC, ntESC, and pESC require the use of oocytes,
and the limited availability of human oocytes poses a signiﬁcantB.V. Open access under CC BY-NC-ND license.
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Fig. 1. Derivation of the various pluripotent stem cells: ESC from a fertilized oocyte, ntESC from a nuclear transferred embryo, pESC from an unfertilized oocyte, and iPSC from
the direct reversion of somatic cells by ectopic expression of four cellular reprogramming factors. Of note, whereas derivation of ESC, ntESC, and pESC utilizes all
reprogramming factors present in the ooplasm, derivation of iPSC involves only the minimal four cellular reprogramming factors present in ESC.
S.C. Tobin, K. Kim / FEBS Letters 586 (2012) 2874–2881 2875obstacle to producing customized ESC (selected from a large ESC
bank) or producing ntESC and pESC suitable for therapeutic use.
Therefore, alternative methods continue to be developed in order
to generate other types of stem cells. In these efforts, ESC continue
to represent the ‘‘gold standard’’ in terms of pluripotency, and are
used as a critical control against which the degree of pluripotency
of new types of derived stem cells is measured (Fig. 1).
In 2006, the generation of induced pluripotent stem cells (iPSC)
by ectopic expression of four reprogramming factors present in ESC
(OCT4, SOX2, KLF4, and MYC) revolutionized the stem cell ﬁeld
[10]. iPSC not only represented a valuable scientiﬁc tool to study
the mechanisms of cellular reprogramming, but also a potentialESC
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Fig. 2. Cellular reprogramming and characteristics of the various pluripotent stem cells.
ESC (center) in terms of pluripotency, genetic/epigenetic errors, imprinted gene status, an
to ESC in each of these areas.source of patient-speciﬁc, histocompatible adult stem cells. Impor-
tantly, the generation of iPSC does not require the use of oocytes, as
the recipient patient would donate his or her own cells to generate
stem cells for autotransplantation. Therefore, iPSC opened up the
possibilities for therapeutic application of pluripotent stem cells
by removing the ethical and histocompatibility limitations of
ESC, ntESC, and pESC (Fig. 1).
Yet while iPSC have a great degree of similarity to ESC, several
reports have also shown signiﬁcant differences in DNA methyla-
tion, gene expression, aberrant reprogramming, and differentiation
potential of iPSC compared with other types of pluripotent stem
cells (Fig. 2). It is now clear that further research is needed toncy 
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d derivation frequency. Improving the quality of iPSC will involve moving iPSC closer
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gramming and to evaluate the characteristics of the resulting plu-
ripotent stem cells—in terms of differentiation potential,
functionality, and safety—if future therapeutic applications of iPSC
are to be realized.
2. Epigenetic and functional differences between ESC and iPSC
Early studies comparing ESC and iPSC at the genome level found
a high degree of similarity in terms of overall gene expression pro-
ﬁle and chromatin modiﬁcation [11–13], with statistical analyses
suggesting that gene expression and chromatin modiﬁcation were
identical in ESC and iPSC. The most stringent test of pluripotency,
tetraploid embryo complementation, has been achieved with a
few mouse iPSC clones, using either iPSC generated from embry-
onic ﬁbroblasts or via serial selection of speciﬁc imprinted gene
expression [14,15]. However, while iPSC are highly similar to ESC
in terms of cell surface marker expression, morphology, teratoma
formation, tissue contribution in chimeric mice, and pluripotent
gene expression, functional analyses of the cells found that iPSC
have reduced differentiation potential toward neural and cardio-
vascular lineages [16,17], and show signs of premature aging
[16,17]. Because ESC are isolated from early-stage embryos and
iPSC are generated from post-natal tissues, ESC and iPSC show dif-
ferential effects of cellular aging on gene expression and epigenetic
alterations.
Because of the observed functional differences between ESC and
iPSC, the ﬁndings of comparative genome-wide analyses have been
challenged on a number of fronts. First, there is the question of
sensitivity. The minimal unit for detecting differential chromatin
modiﬁcation extends across a relatively large region of the chro-
mosome, whereas molecular analyses (e.g., single gene and micr-
oRNA expression) require as few as a hundred base pair regions,
and DNAmethylation analysis is based on a single nucleotide mod-
iﬁcation. Therefore, the sensitivity of molecular analyses is much
higher than that of chromatin modiﬁcation by the nature of the
analysis unit used. Second, overall gene expression proﬁle analysis
of samples from undifferentiated stages of pluripotent stem cells is
problematic. Because pluripotent stem cells co-regulate all pluri-
potency-related genes within a network [18], undifferentiated
stem cells highly express pluripotency genes and suppress genes
that are speciﬁc to differentiated cells. Therefore, the gene expres-
sion patterns in samples from undifferentiated pluripotent stem
cells does not represent the expression patterns in differentiated
pluripotent stem cells and the resulting tissue. Yet the evaluation
of pluripotency depends on the functional differentiation potential
of stem cells. For this reason, gene expression proﬁle analysis of
undifferentiated pluripotent stem cells is limited in its ability to
predict the function of the same genes in stem cell-derived differ-
entiated tissues.
The ﬁnal concern is whether numerical statistics can be applied
to this biological system. While ESC and iPSC are statistically iden-
tical in terms of overall gene expression and chromatin modiﬁca-
tion patterns, it is clear that these two types of stem cells are not
identical in terms of their functional biology. We know that a num-
ber of single gene mutations and epigenetic alterations in a single
chromosomal region can signiﬁcantly impair the function of undif-
ferentiated stem cells and stem cell-derived tissues. As an example,
signiﬁcant functional differences were observed in iPSC that con-
tained a single region of epigenetic alterations in an imprinted
gene [19] and development-related genes [20,21]. Genome-wide
analyses of two stem cell types cannot capture these discrete ge-
netic and epigenetic differences, and so the cells will appear to
be statistically identical. Therefore, it is essential that we examine
these subtle differences between ESC and iPSC—at the level ofsingle gene expression [22], microRNA expression [23], and DNA
methylation [20,21]—to deﬁne the speciﬁc molecular proﬁles of
and the functional differences between the differentiated cells
and tissues that are derived from ESC and iPSC pluripotent stem
cell types.
3. Clonal variability
In the comparative analysis of ESC and ntESC, ntESC showed
much higher clonal variability [24,25]. This epigenetic instability
is due to a systematic instability of reprogramming after the so-
matic cell nuclear transfer procedure. It has been hypothesized
that ntESC generation requires a speciﬁc stoichiometry of repro-
gramming factors from the ooplasm during the ntESC derivation
procedure. As a result, ntESC are often obtained from several hun-
dred nuclear transferred embryos. iPSC show an even greater clo-
nal variability than ntESC; this is primarily because ESC and
ntESC derivation involves a stringent cell selection step in vivo dur-
ing early embryo development that in turn increases the strin-
gency of cell selection in in vitro culture that greatly reduces
stem cell variability. By contrast, iPSC generation involves
in vitro culture of somatic cells after introduction of four repro-
gramming factors. These factors include the well-known oncogene,
Myc, which supports rapid and uncontrolled growth of the cells on
the tissue culture plate. iPSC colonies are then selected based on
morphological criteria. As a result, the stringency of iPSC selection
is much lower than that of ESC and ntESC. To overcome the clonal
variability of iPSC, reporter genes have been expressed under the
control of promoters of pluripotency-related genes such as OCT4
and NANOG; however, pluripotent stem cell marker-based selec-
tion depends on the expression of only one pluripotent reporter
gene, and this approach is not likely to be applied to human iPSC.
Clonal variability can be reduced by more faithful reprogramming
of iPSC, but how to achieve this is a crucial question for future re-
search that must be answered before clinical application of iPSC to
human tissue replacement therapy.
4. Tissue-speciﬁc epigenetic memory
Reprogramming of somatic cells to produce iPSC is incomplete,
and leaves residual epigenetic markers—DNA methylation, chro-
matin modiﬁcation, and transcriptional regulation—in the result-
ing iPSC genome. Recent genome-wide DNA methylation studies
[19,20] showed that reprogrammed iPSC contain the DNA methyl-
ation signature of the tissue of origin. Compared with the gold
standard of pluripotency, ESC, ntESC exhibited a much smaller tis-
sue-speciﬁc epigenetic signature than did iPSC generated from dif-
ferent somatic cell origins (blood, ﬁbroblast, and brain) [20]. We
concluded that this was due to an incomplete reset of the tissue-
speciﬁc epigenetic signature to the default embryonic stages dur-
ing iPSC reprogramming. In functional analyses, the residual tis-
sue-speciﬁc epigenetic DNA methylation signature affected the
differentiation potential and function of the cells and tissues de-
rived from iPSC, favoring differentiation to the tissue of origin. Nei-
ther ntESC nor ESC showed this preferential tissue differentiation
potential. While these ﬁndings indicated that epigenetic memory
in iPSC directs tissue differentiation, the study also showed that
this epigenetic memory interferes with current tissue differentia-
tion protocols. Nevertheless, identifying the unique epigenetic sig-
natures in iPSC-derived from various somatic cell origins will
inform efforts to enhance tissue differentiation from pluripotent
stem cells toward certain tissue lineages.
Although the differentiation potential of iPSC has been demon-
strated, producing blood, pancreatic beta cells, and cardiac muscle
[21,26,27], tissue-speciﬁc epigenetic memory can interfere with
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during tissue development in the embryo, at certain stages of so-
matic cell differentiation and de-differentiation under tightly reg-
ulated gene expression. During differentiation of iPSC, the
residual epigenetic memory can alter these highly controlled pat-
terns of gene expression, resulting in lower differentiation efﬁ-
ciency and abnormal function of the resulting cells and tissues.
With the ultimate goal of using iPSC in therapeutic applications,
it is crucial that the epigenetic memory in iPSC be minimized. In
terms of epigenetic signature, ntESC more closely resemble ESC
and are thus a better source of pluripotent stem cells than iPSC
(Fig. 2).
5. Dissection of the epigenetic changes during iPSC
reprogramming
Recent studies of human iPSC compared with ESC and somatic
cells suggest that high-resolution DNA methylation analysis may
be a better approach to dissecting the epigenetic changes that oc-
cur during iPSC reprogramming [21,28]. In this approach, differen-
tially methylated regions (DMRs) are identiﬁed in iPSC and
compared with those in ESC and somatic cells, allowing the identi-
ﬁcation of the source of the DMRs during reprogramming. Surpris-
ingly, only half of the DMRs were deﬁned as related to incomplete
reprogramming and decreased pluripotency, whereas the other
half of the DMRs were identiﬁed as an epigenetic errors that were
not found in either somatic cells or ESC. These methylation errors
were transmitted to the iPSC-derived differentiated tissues [28].
In examining the relationship between cellular reprogramming
and pluripotency, we can consider that the generation of ESC after
fertilization involves cellular reprogramming of the sperm and oo-
cyte. During early embryo development, the sperm- and oocyte-
speciﬁc epigenetic memory must be erased to the default stage,
and the epigenetic signature of the ESC must be established to
complete cellular reprogramming. The derivation of ntESC mimics
the cellular reprogramming of the ESC, similarly erasing the epige-
netic memory in the somatic cell nucleus to the default stage, and
re-establishing the ntESC epigenetic signature. In both cases, fewer
epigenetic errors are incorporated into the resulting ntESC and ESCExtended tissue culture
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Fig. 3. Approaches to erasing tissue-speciﬁc epigenetic memory and evaluating the resu
and modiﬁcation of the iPSC reprogramming procedure (bottom) have been suggested to
compared not only with iPSC from different tissues but also with ESC as the gold stan
different during extended tissue culture and with variations in iPSC reprogramming;
therapeutic utility of the resulting cells.compared with iPSC (Fig. 2). This indicates that, to reach a plurip-
otent state, iPSC reprogramming may proceed down a different
pathway than in either ESC or ntESC, or iPSC may be missing
important components that protect against abnormal epigenetic
alterations that occur during reprogramming. How to reduce the
number of epigenetic errors that arise during iPSC reprogramming
and increase the quality of iPSC remains to be investigated.
6. Alteration of imprinted genes
Imprinting is a well-conserved epigenetic signature in various
organisms, which evolutionarily discriminate between male- and
female-speciﬁc gene expression established during sperm and oo-
cyte development. The combination of the two imprinted gene
expression patterns upon fertilization determines the balance of
gene expression during embryo development. Abnormal regulation
of imprinting often causes altered gene expression. Only the pres-
ence of an additional copy of the gene from either the paternal or
maternal chromosome is sufﬁcient to induce altered phenotypes,
such as a developmental defect, tissue differentiation, or oncoge-
nicity. Imprinted genes are erased during early germ cell develop-
ment, and are re-established upon full development of the sperm
and oocyte. As described above, epigenetic reprogramming to re-
vert somatic cells to an embryonic stage must induce genome-
wide epigenetic modiﬁcations that erase the tissue-speciﬁc epige-
netic signature to a default stage, and then re-establish the appro-
priate tissue-speciﬁc signatures during differentiation of the
pluripotent stem cells. During early-stage reprogramming, either
by fertilization (reprogramming of the sperm and oocyte to create
a zygotic embryo) or by nuclear transfer of a somatic cell nucleus
to an enucleated oocyte (reprogramming of the somatic nucleus
by factors in the ooplasm) [29], imprinted genes are protected from
genome-wide epigenetic changes. Because pESC originate from
unfertilized oocytes, these stem cells contain only female-speciﬁc
imprinting; these oocyte-speciﬁc imprinted genes are protected
during the pESC derivation procedure. By contrast, iPSC repro-
gramming is less discriminate, and imprinted regions are also al-
tered, which frequently damages their epigenetic signature.
Aberrant silencing of imprinted genes during iPSC reprogrammingESC
iPSC
No significant 
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lting pluripotent stem cells. Extended tissue culture after iPSC reprogramming (top)
increase the quality of the resulting iPSC. In both cases, the resulting cells need to be
dard of pluripotency. Genetic and epigenetic stability and alteration rates will be
therefore, rigorous veriﬁcation procedures are required to evaluate the potential
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lected that did not contain abnormal imprinted genes and were
used to generate normal differentiated tissue as well as full-term
mice by tetraploid complementation (Fig. 3) [15,30].
7. Approaches to correcting the iPSC epigenetic signature
Among the various pluripotent stem cells, ntESC are closer to
the gold standard of ESC than any other pluripotent stem cell type,
in terms of both molecular signature and function (Fig. 2) [20].
Although iPSC hold signiﬁcant potential for therapeutic use and
provide an alternative human stem cell research material, aberrant
epigenetic alterations affect the differentiation potential and func-
tion of the resulting cells and tissues. Thus, a major interest in the
pluripotent stem cell ﬁeld is how to correct the iPSC epigenetic sig-
nature to produce high-quality pluripotent stem cells that are
more similar to ESC in terms of differentiation potential, function,
and, for clinical applications, safety. The functional phenotypes
that we observe are limited, and there are no standard protocols
to test all aspects of pluripotency, oncogenicity, and tissue function
of iPSC. Therefore, epigenetic signatures determined by molecular
analysis are often used as surrogate indicators of iPSC quality.
Epigenetic memory in iPSC can be erased by extended tissue
culture [19], although it is not yet clear whether the extended cul-
ture of iPSC also improves their pluripotency, moving them closer
to ESC (Fig. 3). However, use of earlier passages of pluripotent stem
cells is favored in therapeutic applications to avoid genetic and epi-
genetic alterations that arise during extended tissue culture. Alter-
natively, application of a chromatin modifying drug (trichostatin A)
[31] and a DNA demethylation agent (5-aza-cytidine) [32] can
erase the epigenetic memory if iPSC, and can restore the ability
to differentiate to various tissue lineages, different from the tissue
of origin. Again, this approach is not ideal for therapeutic applica-
tions because these drug treatments do not improve the pluripo-
tency of iPSC (i.e., move them toward ESC), and most likely
damage other regions of the DNA that should not be modiﬁed, such
as those containing imprinted genes.
Therefore, fundamental studies are needed to determine how to
erase tissue-speciﬁc epigenetic memory in iPSC in order to gener-
ate better quality pluripotent stem cells that more closely resemble
ESC. The ﬁrst step will be to characterize the genetic and epigenetic
differences between human ESC and iPSC. To achieve this, tight
control of sampling procedures and a large numbers of samples
from each stem cell type will be required, as it is especially difﬁcult
to control for the genetic backgrounds of human ESC and iPSC. In-
deed, the detection of epigenetic differences between ESC and iPSC
in humans has been limited by the collection of donor cells under
genetically and epigenetically well-controlled conditions. Never-
theless, tissue-speciﬁc epigenetic memory in human iPSC has been
veriﬁed by examining the differentiation potential of iPSC to their
various tissues of origin, such as skin, blood, and pancreas [21,26].
The tissue-speciﬁc molecular signatures of human iPSC show the
same DNA methylation patterns as those seen in mouse iPSC.
Parallel to efforts in erasing tissue-speciﬁc epigenetic memory
in iPSC, it is also important to investigate ways to alter current iPSC
reprogramming strategies to overcome the limitations posed by
residual epigenetic modiﬁcations (Fig. 3). Because ntESC do not
contain tissue-speciﬁc epigenetic memory, and are therefore more
similar to ESC, we believe that the ooplasm contains additional fac-
tors needed to completely erase the tissue-speciﬁc epigenetic
memory. There is an ongoing search for these additional factors,
as well as research into the events that occur during ntESC repro-
gramming. One of the most interesting studies in this area asked
whether the ooplasm is able to reverse the incomplete reprogram-
ming status of iPSC after iPSC nuclear transfer to and enucleatedoocyte [27]. Interestingly, iPSC nuclear transfer was unable to re-
cover the poorly reprogrammed iPSC and produce faithfully repro-
grammed pluripotent stem cells, which was demonstrated by
generating iPSC-derived mice. Gene expression analysis also con-
ﬁrmed that the iPSC-ntESC clustered away from other pluripotent
stem cells, with signiﬁcant dissimilarity from ESC, despite the fact
that both stem cell types utilize ooplasm reprogramming factors.
These results indicated that the epigenetic alterations in iPSC are
preserved after the nuclear transfer procedure, and a large portion
of the aberrant epigenetic signatures in iPSC are permanent.
Further analysis is also needed of iPSC generated using different
transgene introduction methods (e.g., RNA, adenovirus, and piggy-
Bac virus), and containing various combinations of additional
reprogramming factors to understand the effect on epigenetic
alterations, tissue differentiation, safety, and tissue function in var-
ious therapeutic models.
8. Genomic integrity of iPSC
Cellular reprogramming leads to changes in epigenetic markers
that then alter cellular properties and function. However, epige-
netic alteration cannot be considered independent of genetic
changes. Epigenetic modiﬁcation induces differential gene expres-
sion patterns, including genes related to genomic integrity, which
are frequently linked with cancer progression [33]. The genomic
integrity of iPSC was deﬁned by genome-wide DNA sequencing
of 22 independent iPSC-derived from the various sources [34]. iPSC
were found to contain a higher rate of DNA mutation. While half of
the mutations existed at a low level in the donor somatic cells, the
other half were de novo mutations that arose during the iPSC
reprogramming procedure. Interestingly, the majority of the
iPSC-speciﬁc mutations were related to oncogenicity, which raised
serious concerns regarding the potential clinical application of
iPSC. The results of this study implied that iPSC reprogramming en-
riched for an oncogenic genetic signature that is not seen during
ESC derivation. Signiﬁcantly higher copy number variations (CNVs)
were also observed in iPSC compared with ESC and ﬁbroblasts [35].
CNVs remained high during iPSC reprogramming and then gradu-
ally decreased during extended tissue culture. It has been hypoth-
esized that progressive negative selection occurs against higher
CNVs in the cultured cells. However, it is still not clear how CNVs
are increased during iPSC reprogramming; this may be caused by
either a selective advantage or active accumulation during the iPSC
reprogramming process.
9. Key developmental regulators for pluripotency
As described above, the goal of iPSC research is to improve the
faithful reprogramming of iPSC, mimicking as closely as possible
the events that occur in the generation of ESC in the developing
embryo, to produce high-quality iPSC that can be used for clinical
applications. The dramatic developmental transitions that accom-
pany early embryonic development and gastrulation are induced
and regulated by environmental stimuli that include hormones,
morphogens, and extracellular matrix proteins. Cell differentiation
and the adoption of stable, irreversible cell fates involve the con-
certed action of transcription factors followed by consolidation of
transcriptional programs through stable epigenetic modiﬁcations.
The octamer-binding transcription factor 4 (OCT4), a central player
in the early embryo, is zygotically expressed at the 4- to 8-cell
stage and its continued expression deﬁnes the inner cell mass
(ICM) of the blastocyst [36]. A zone of trophoblastic speciﬁcation
in the outer ‘‘rind’’ or ‘‘crust’’ cells of the compacting morula is
established by the down-regulation of OCT4 [37]. In this cell fate
choice within the mammalian embryo, OCT4 acts as a negative
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regulator of the pluripotent capacity of the ICM [37,39,40]. OCT4-
null embryos fail to form the ICM. Instead, all cells default to troph-
ectoderm [37]. A simple lack of OCT4 expression may be insufﬁ-
cient to elicit a default towards trophectoderm and may
additionally require the expression of transcription factors like
CDX2 and EOMES. Both CDX2 and EOMES expression is restricted
to the trophectoderm. CDX2 [41] and EOMES [42] knockout em-
bryos fail to implant, further indicating that both genes are re-
quired in trophectodermal development. Transient expression of
OCT4 is observed in the hypoblast just prior to the speciﬁcation
of parietal and visceral endoderm (which don’t express OCT4), sug-
gesting that ephemeral up-regulation of OCT4 further commits
hypoblast differentiation [43]. OCT4 regulates several genes during
early embryonic development, including SOX2, NANOG [44], FGF4,
REX1, OPN, hCG, UTF1, creatine kinase B, Makorin 1, Importin, His-
tone H2A.Z, Ribosomal protein S7 [45], and INF [46]. OCT4 is also
expressed in undifferentiated embryonic carcinoma (EC) cells,
embryonic germ (EG) cells, and ESC. Continuous expression of
OCT4 appears necessary but not sufﬁcient to maintain pluripoten-
cy in embryonic cells [38].
In the blastocyst, expression of ﬁbroblast growth factor 4 (FGF4)
deﬁnes the ICM/epiblast, while expression of the FGF receptor 2
(FGFR2) deﬁnes trophectoderm [47]. FGF4 appears to serve as a
paracrine signal for trophectoderm proliferation or differentiation
[48]. The transcription factor SOX2 shows a similar expression pat-
tern to that of OCT4 during early embryonic development, with the
exception that it is continuously expressed in trophectoderm [49].
SOX2 is important in lineage speciﬁcation, as SOX2 and OCT4 to-
gether regulate FGF4 expression within the epiblast, which is
essential for proliferation of the trophectoderm [49]. SOX2 expres-
sion is also required for the formation of the ICM and epiblast [49].
SOX2 and OCT4 are co-expressed in the morula, ICM, epiblast, and
germ cells, implying collaborative function in the maintenance of
pluripotency [50]. SOX2 mutants demonstrate reduced cellular
proliferation, leaving only trophoblast giant cells and extraembry-
onic ectoderm. Such mutants do not prevent formation of the blas-
tocyst cavity, although the ICM is missing. Thus, in the murine
SOX2 knockout model, ESC cannot be derived and the mice are
not viable past early embryonic development. Epiblast defects in
the Sox2 mutant can be rescued by the injection of wild-type
ESC [49].
NANOG is a critical transcriptional factor underlying pluripo-
tency in both ESC and EG cells [51]. Immunocytochemical analysis
demonstrates that the NANOG protein is present in the nuclei of
cells in morula-stage embryos, the ICM, and the epiblast, but not
in primordial germ cells (PGC), the intraembryonic mesoderm,
and extraembryonic endoderm. NANOG deﬁciency triggers the dif-
ferentiation of ESC to the extraembryonic endoderm lineage, sug-
gesting that this DNA-binding protein acts in part by
transcriptionally repressing key regulators of this alternative tissue
fate. NANOG-null embryos are unable to support the formation of
the epiblast and also fail to generate ESC, producing only endoder-
mal derivatives [51]. NANOG cannot be detected in OCT4-positive
PGCs, supporting the hypothesis that regulation of NANOG expres-
sion may come from mechanisms independent of OCT4 or by the
concerted action of OCT4 and other factors. OCT4 and NANOG have
both been implicated in the maintenance of pluripotency. Overex-
pression of NANOG promotes the expansion of ESC independent of
leukemia inhibitory factor (LIF), STAT3, and OCT4 pathways, sug-
gesting that NANOG is important for self-renewal in ESC and cells
of the early embryo [52]. The expression patterns of NANOG and
OCT4 are not identical. NANOG turns over rapidly [51]. Thus, it is
only proliferating ESC that are double-positive for OCT4 and NA-
NOG. Recently, it was shown that a culture regimen including bone
morphogenic proteins (BMPs) and LIF under serum-free andfeeder-free conditions supports pluripotency of ESC, while over-
expressing NANOG eliminates the need for BMPs [53]. Therefore,
NANOG maintains the pluripotency of ESC independent of the
LIF-STAT3, BMP, and OCT4 pathways.10. The essential iPSC reprogramming factors
Reprogramming of somatic cells into iPSC relies on the ectopic
expression of four transcription factors (OCT4, SOX2, KLF4, and
MYC), which are highly expressed in ESC [10]. Two additional fac-
tors (NANOG and LIN28) have been identiﬁed that enhance iPSC
reprogramming; these factors are mechanistically associated with
the four essential reprogramming factors [54]. OCT4, SOX2, KLF4,
and MYC are predicted to have unique functions. OCT4 and SOX2
induce the pluripotent gene regulatory pathway, and enhance
expression of NANOG. KLF4 is known to interact with pluripotency
network proteins including OCT4 and SOX2, and also inhibits cell
death. MYC is dispensable for reprogramming but is important to
regulate chromatin structure to facilitate cellular reprogramming
[55]. MYC is mechanistically associated with LIN28, which is a
downstream target that enhances MYC expression. LIN28 is also
involved in microRNA regulation by inhibition of LET7 family pro-
teins, which are important for tissue differentiation [56]. Depend-
ing on the donor tissue types and the reprogramming method
used, additional reprogramming factors are not required for iPSC
reprogramming [57]. However, how the requirement for the cellu-
lar reprogramming is controlled and how the cellular regulatory
pathways are established during cellular reprogramming need to
be further deﬁned. Although the individual function of each repro-
gramming factor in somatic cells has been studied, the synergistic
interactions of all four factors and their contribution to the overall
reprogramming process still need to be understood.
Although these reprogramming factors are expressed in somatic
cells using an inducible promoter, reprogramming efﬁciency is still
below 0.1–1% [58]. This indicates that reprogramming is not a uni-
directional process in all cells, and variable epigenetic differences
select for subpopulation of cells to generate iPSC. Due to the low
reprogramming efﬁciency, we cannot isolate cells at intermediate
stages of iPSC reprogramming, and a detailed analysis of the epige-
netic changes that occur during cellular reprogramming has been
challenging. Developing methods to select intermediate forms of
reprogrammed iPSC will allow us to study the epigenetic changes
that occur throughout the iPSC reprogramming. In addition, these
intermediate forms will help us discover factors or new approaches
that can overcome the genetic and epigenetic abnormalities of
iPSC, and new ways to increase reprogramming speciﬁcity such
that only pluripotency-related genomic regions are altered. To-
gether, this research will move us closer to generating iPSC of
equivalent quality to ESC, and realizing the opportunities for using
iPSC to safely and reliably generate patient-speciﬁc, histocompati-
ble transplantable tissues and cells.11. Future perspectives: investigating other pluripotent stem
cells beyond iPSC
iPSC have the potential to provide enormous beneﬁt, not only
for future therapeutic applications but also as research tools to
clarify the mechanism of cellular reprogramming of terminally dif-
ferentiated aged tissue to the embryonic stage. A number of re-
ports have demonstrated that iPSC are highly similar to the
pluripotency gold standard ESC, and could substitute for multiple
types of the pluripotent stem cells. More careful analysis has
shown that iPSC are not identical to ESC in terms of their molecular
signature, differentiation potential, and function. To improve the
quality of iPSC, basic studies on the regulatory mechanisms present
2880 S.C. Tobin, K. Kim / FEBS Letters 586 (2012) 2874–2881in the developing embryo is needed to identify the key factors in-
volved in the generation of pluripotent ESC. As such, research in
ESC biology has become even more valuable since the introduction
of iPSC reprogramming methods, and these cells continue to serve
as the gold standard of the pluripotency as we move forward in the
development of other stem cell lines. Yet we must also continue to
study the mechanisms governing reprogramming after nuclear
transfer in ntESC, in order to understand what other factors may
improve iPSC quality and pluripotency for use in regenerative
medicine. While iPSC mimic the cellular reprogramming procedure
in ntESC by activating the few essential factors necessary to reverse
differentiation of a somatic cell, the reprogramming factors present
in the enucleated oocyte more efﬁciently and faithfully reprogram
the somatic cell nucleus [20], in both molecular signature and dif-
ferentiation potential. We are therefore obligated to study the dif-
ferences in reprogramming that occur during the nuclear transfer
procedure and during the generation of iPSC to discover those fac-
tors that will promote faithful iPSC reprogramming. Another chal-
lenge in the development of iPSC is that these cells often show
alterations in imprinting [15]. This imprinting damage is also ob-
served in ntESC [24]. Studies with pESC and androgenetic ESC
(aESC) derived from a uniparental origin are needed in order to
investigate the epigenetic signature of the imprinted genes and
how they impact the pluripotency and function of the stem cells.
In conclusion, although there are many reasons—ethical, immuno-
logical, and technical—for using iPSC rather than other pluripotent
stem cells, a great deal of research on all stem cell types is still
needed in order to achieve high-quality iPSC that are suitable for
clinical application in tissue replacement therapy. It is therefore
essential that the public and policymakers recognize the impor-
tance of understanding the mechanistic relationships among the
various pluripotent stem cells and that supporting research on only
one stem cell type will not only obstruct the scientiﬁc community’s
efforts, but also impede progress in regenerative medicine that will
improve human health and well-being.
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